ranibizumab
Selected indexed studies
- Ranibizumab for myopic choroidal neovascularization. (Expert Opin Biol Ther, 2020) [PMID:33003962]
- Ranibizumab. (Drugs, 2007) [PMID:17521219]
- Ranibizumab: A Review in Retinopathy of Prematurity. (Paediatr Drugs, 2021) [PMID:33447937]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ranibizumab for myopic choroidal neovascularization. (2020) pubmed
- Ranibizumab. (2007) pubmed
- Ranibizumab: A Review in Retinopathy of Prematurity. (2021) pubmed
- Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. (2012) pubmed
- Ranibizumab for the treatment of diabetic retinopathy. (2021) pubmed
- Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution? (2024) pubmed
- Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. (2017) pubmed
- SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. (2017) pubmed
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. (2019) pubmed
- Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. (2022) pubmed